After a period of reduced funding in the biotechnology sector, investors anticipate that 2026 will see ongoing mergers and acquisitions as well as increased dealmaking. There is also an expectation of more diversified investments beyond traditional areas such as oncology and immunology.
This outlook was discussed on a recent episode hosted by Jennifer Smith-Parker, Director of Insights at BioSpace. The panel included Maha Katabi, General Partner at Sofinnova Investments, and Andrew Lam, Managing Director and Head of Biotech Private Equity at Ally Bridge Group (ABG).
The guests shared their perspectives on the future direction of biotech investing. The discussion highlighted optimism for renewed activity in the sector after what has been described as a "prolonged funding chill." Both speakers emphasized that investor interest is expanding into new therapeutic areas.
A disclaimer noted: "The views expressed in this discussion by guests are their own and do not represent those of their organizations."
